ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Cost Analysis of ED Drugs in the United States
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 270619" data-attributes="member: 13851"><p><strong>Abstract</strong></p><p><strong></strong></p><p><strong>Objective</strong></p><p></p><p><em>To perform a cost analysis of generic and brand-name PDE5 inhibitors at different dosages and pharmacies across the US.</em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em>Using an all-payer retail pharmacy claims database, we analyzed prescription drug data for <strong>three generics and six brand-name oral PDE5 inhibitors at different dosages across the US chain and independent pharmacies in 2019.</strong></em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em><strong>We obtained cash price data from 60,186 pharmacies (35,976 chains and 24,210 independent).</strong> <strong>The nationwide mean cash price per unit (PPU) ranged from $8.6±5.2 (sildenafil 20mg at chain pharmacies) to $107.1±71 (Adcirca 20mg at independent pharmacies) equal to a 1,145.3% difference.</strong> Chain pharmacies provided significantly lower average prices for one brand name and six generic PDE5 inhibitors. Tadalafil PPU was cheaper at higher quantities, however, PPU increased with the quantity prescribed for sildenafil.<strong> Looking at the top 10 metropolitan statistical areas, the highest PPUs were observed for tadalafil (Cialis) 10mg and sildenafil (Viagra) 50mg in Atlanta ($67.4±8.7) and Los Angeles ($50.3±24.0), while New York ($9.7±2.6) and Miami Journal Pre-proof3 ($27.9±16.4) had the lowest PPUs for tadalafil (Cialis) 5mg and sildenafil (Viagra) 100mg, respectively.</strong></em></p><p><em><strong></strong></em></p><p><em><strong></strong></em></p><p><em><strong>Conclusion</strong></em></p><p><em></em></p><p><em>A substantial variability in PDE5 inhibitor cash prices exists across manufacturer, dosage, quantity, pharmacy type, and location. In addition, the pricing does not necessarily correlate with the regional socioeconomic factors. This highlights the importance of provider awareness and patient counseling on drug price including potentially assisting patients in identifying opportunities for cost savings.</em></p><p></p><p></p><p></p><p></p><p><strong>5. Conclusions</strong></p><p><strong></strong></p><p><strong><em>Although PDE5 inhibitors have been proven to be an effective class of drugs for ED, their use is sometimes limited due to cost. Using a large nationwide sample of Journal Pre-proof 15 pharmacies, we found substantial variability in PDE5 inhibitor cash prices by retail pharmacy type, manufacturer, dosage, and quantity. We also found the pricing does not necessarily correlate with the regional socioeconomic factors. This highlights the importance of provider awareness and patient counseling on drug price including potentially assisting patients in identifying the most affordable medication regimen. <u>This study could pave the road toward increased affordability, adherence, and inclusion in the use of this highly effective class of medications</u>.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 270619, member: 13851"] [B]Abstract Objective[/B] [I]To perform a cost analysis of generic and brand-name PDE5 inhibitors at different dosages and pharmacies across the US.[/I] [B]Methods[/B] [I]Using an all-payer retail pharmacy claims database, we analyzed prescription drug data for [B]three generics and six brand-name oral PDE5 inhibitors at different dosages across the US chain and independent pharmacies in 2019.[/B][/I] [B]Results[/B] [I][B]We obtained cash price data from 60,186 pharmacies (35,976 chains and 24,210 independent).[/B] [B]The nationwide mean cash price per unit (PPU) ranged from $8.6±5.2 (sildenafil 20mg at chain pharmacies) to $107.1±71 (Adcirca 20mg at independent pharmacies) equal to a 1,145.3% difference.[/B] Chain pharmacies provided significantly lower average prices for one brand name and six generic PDE5 inhibitors. Tadalafil PPU was cheaper at higher quantities, however, PPU increased with the quantity prescribed for sildenafil.[B] Looking at the top 10 metropolitan statistical areas, the highest PPUs were observed for tadalafil (Cialis) 10mg and sildenafil (Viagra) 50mg in Atlanta ($67.4±8.7) and Los Angeles ($50.3±24.0), while New York ($9.7±2.6) and Miami Journal Pre-proof3 ($27.9±16.4) had the lowest PPUs for tadalafil (Cialis) 5mg and sildenafil (Viagra) 100mg, respectively. Conclusion[/B] A substantial variability in PDE5 inhibitor cash prices exists across manufacturer, dosage, quantity, pharmacy type, and location. In addition, the pricing does not necessarily correlate with the regional socioeconomic factors. This highlights the importance of provider awareness and patient counseling on drug price including potentially assisting patients in identifying opportunities for cost savings.[/I] [B]5. Conclusions [I]Although PDE5 inhibitors have been proven to be an effective class of drugs for ED, their use is sometimes limited due to cost. Using a large nationwide sample of Journal Pre-proof 15 pharmacies, we found substantial variability in PDE5 inhibitor cash prices by retail pharmacy type, manufacturer, dosage, and quantity. We also found the pricing does not necessarily correlate with the regional socioeconomic factors. This highlights the importance of provider awareness and patient counseling on drug price including potentially assisting patients in identifying the most affordable medication regimen. [U]This study could pave the road toward increased affordability, adherence, and inclusion in the use of this highly effective class of medications[/U].[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Cost Analysis of ED Drugs in the United States
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top